This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of the Safety of R256918 in Obese Patients

This study has been completed.
Information provided by (Responsible Party):
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Identifier:
First received: December 30, 2009
Last updated: January 15, 2013
Last verified: January 2013
This study investigates the safety of 12 weeks of treatment with R256918, in obese patients (JNJ-16269110 and R256918 are different names for the same molecule). The primary objective of the study is to investigate mean changes in Hepatic Triglyceride Content (HTGC), which is the fat content of the liver, from baseline to week 6 and 12 by 1H-Magnetic Resonance Spectroscopy (MRS), a specialized non invasive radiology test. Additional measures include body mass index (BMI), fasting glucose,lipid levels, and blood pressure. Safety assessments performed during the trial include laboratory tests, vital sign measurements, and adverse event reporting.

Condition Intervention Phase
Obesity Nutritional and Metabolic Diseases Metabolic Diseases Nutrition Disorders Overweight Drug: R256918 Drug: placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-Center Study to Evaluate the Effect of JNJ-16269110 on Hepatic Triglyceride Content in Obese Subjects

Further study details as provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:

Primary Outcome Measures:
  • Hepatic Triglyceride Content (HTGC) as measured by 1H-Magnetic Resonance Spectroscopy (MRS). [ Time Frame: Baseline, 6 weeks, 12 weeks ]

Secondary Outcome Measures:
  • Change in Body weight [ Time Frame: Baseline, weeks 1, 2, 4, 6, 8,10,12,14 ]
  • Change in alanine aminotransferase and aspartate aminotransferase [ Time Frame: Baseline, weeks 4, 6, 8,12,14 ]
  • Changes in fasting glucose and insulin [ Time Frame: Baseline, weeks 6, 12 ]
  • Changes in systolic and diastolic blood pressure [ Time Frame: Baseline, weeks 1, 2, 4, 6, 8, 10, 12, 14 ]
  • Changes in total-, HDL- and LDL-cholesterol and triglycerides [ Time Frame: Baseline, weeks 6,12 ]

Enrollment: 71
Study Start Date: February 2008
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 001
R256918 10 mg capsule twice daily
Drug: R256918
10 mg capsule twice daily
Experimental: 002
R256918 15 mg capsule twice daily
Drug: R256918
15 mg capsule twice daily
Placebo Comparator: 003
placebo placebo capsule twice daily
Drug: placebo
placebo capsule twice daily

Detailed Description:
This is a randomized (study drug assigned by chance), double-blind (neither physician nor patient knows the name of the assigned drug), placebo-controlled , parallel-group study with 3 treatment arms, each consisting of 27 obese patients. The study will include 3 phases - pretreatment, double-blind and posttreatment . During the pretreatment phase patients undergo general screening assessments and if eligible, Magnetic Resonance Spectroscopy (MRS) screening will be performed. During the double-blind treatment phase patients will receive dietary counseling, study medication, have urine and blood laboratory tests, a follow up MRS examination and have regular clinic visits for symptoms assessment. The double blind treatment phase ends with an end-of-treatment or early withdrawal visit. A patient withdrawing from the study prior to the end of the 12 week treatment phase will attend an early withdrawal visit, which is the same as the end-of-treatment visit. This visit will include laboratory tests and a follow up MRS examination. Post-treatment: A follow-up evaluation will occur 14 days after the end of treatment. Study visits are scheduled to occur nearly every 14 days following the baseline visit in week 1. The total study duration is approximately 15 weeks. The study will include the following evaluations of safety and tolerability: mean percent change in liver fat content at week 6 and week 12 or at the end of the patients participation in the study, in case of early withdrawal. Safety evaluations for the study will include the monitoring of adverse events, clinical laboratory tests including pregnancy testing, electrocardiograms (ECGs), vital sign measurements (pulse and blood pressure), physical examination, and patient reported assessment of GI symptoms. Special clinical laboratory safety tests will assess blood clotting or coagulation status, essential fatty acid status, lipid-soluble vitamin status: vitamin A, vitamin D, vitamin E, vitamin K, vitamin A/total cholesterol ratio, vitamin E/total cholesterol ratio and liver function tests. 10 mg capsules, 15 mg capsules, or matching placebo capsules taken orally.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Liver fat content (HTGC) between 3% and 15%
  • Obese defined as BMI between 30 and 50 kg/square meter
  • Fasting plasma glucose < 7.0 mmol/liter

Exclusion Criteria:

  • History of Obesity with a known cause (eg. Cushings disease)
  • Diabetes Mellitus
  • Weight reducing diet or receiving drugs to treat obesity within 3 months prior to screening
  • Significant change in smoking habits within 3 months before enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01041677

Helsinki, Finland
Zuidlaren, Netherlands
Göteborg, Sweden
Sponsors and Collaborators
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Study Director: Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
  More Information

Additional Information:
Responsible Party: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Identifier: NCT01041677     History of Changes
Other Study ID Numbers: CR013735
Study First Received: December 30, 2009
Last Updated: January 15, 2013

Keywords provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:
Body Weight
Body Size
Nutritional and Metabolic Diseases

Additional relevant MeSH terms:
Metabolic Diseases
Nutrition Disorders
Body Weight
Signs and Symptoms processed this record on September 21, 2017